1 tablet 5mg

5 cents

Accupril, Accuretic (quinapril + hydrochlorthiazide)

  • Hypertension

  • Congestive heart failure or left ventricular dysfunction after myocardial infarction

  • Diabetic nephropathy

PO
Accupril tablets 5mg, 10mg & 20mg (reddish-brown)
Accuretic tablets 10mg quinapil & 12.5mg hydrochlorthiazide (pink)


ADULT DOSE

PO:
5-10mg once daily; increasing to 20-40mg daily as required

PAEDIATRIC DOSE

PO:
0.2-0.8mg/kg daily

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY
Dose in renal impairment [GFR (ml/min)]
<10 50% of normal dose
10-20 75-100% of normal dose
>20-50 75-100% of normal dose

Dose in renal replacement therapy
CAPD 50% of normal dose
HD 75-100% of normal dose
CVVHDF 75-100% of normal dose

Note: Recent clinical observations have shown an association of hypersensitivity-like (anaphylactoid) reactions during haemodialysis with high-flux dialysis membranes (e.g., AN69) in patients receiving ACE inhibitors.

Quinapril is a specific competitive inhibitor of angiotensin I-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I to angiotensin II.

CONTRAINDICATIONS:

  • Hypersensitivity to quinapril or any other angiotensin-converting enzyme inhibitor (e.g. a patient who has experienced angioedema during therapy with any other ACE inhibitor).

  • Cardiogenic shock


WARNINGS
Anaphylactoid and Possibly Related Reactions
Quinapril can cause anaphylactoid reactions
Head and Neck Angioedema
Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of quinapril; some cases required medical therapy.
Intestinal Angioedema
Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal.
Neutropaenia/Agranulocytosis
Neutropaenia (<1000/mm3) with myeloid hypoplasia has resulted from use of quinapril.
Hypotension in Heart Failure Patients
Caution should be observed when initiating therapy in patients with heart failure. Patients with heart failure given quinapril commonly have some reduction in blood pressure. In patients with symptomatic hypotension this may require temporarily reducing the dose of quinapril, or diuretic, or both, and volume repletion
Hepatic Failure
Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor.

PRECAUTIONS
General
Some patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in serum creatinine after reduction of blood pressure with quinapril. Quinapril dosage reduction and/or discontinuation of diuretic may be required.
Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including quinapril.
Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.

Laboratory Tests:
No tests in addition to routine ICU tests are required.

Drug/Laboratory Test Interactions :
None known.

Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
The risk of hypotension increases if quinapril is coadministered with other antihypertensives.

Body as a Whole:
Gynaecomastia, anaphylactoid reactions, angioedema
Cardiovascular:
Cardiac arrest, cerebrovascular accident / insufficiency, rhythm disturbances, orthostatic hypotension, syncope
Dermatological:
Bullous pemphigus, erythema multiforme (Stevens Johnson syndrome), exfoliatice dermatitis
Gastrointestinal:
Pancreatitis, glossitis, dyspepsia, jaundice, hepatitis, rare causes of hepatic necrosis, cholestasis
Haematological:
Anaemia (including cases of haemolytic anaemia), thrombocytopaenia, neutropaenia
Metabolic:
Hyponatraemia
Musculoskeletal:
Myalgia, myasthenia
Nervous system:
Ataxia, confusion, depression, nervousness, somnolence
Respiratory system:
Bronchospasm, eosinophilic pneumonia, angioedema
Urogenital system:
Renal failure, proteinuria

[an error occurred while processing this directive]